[{"id":"84a680b4-a96a-45c2-825f-d8e10004766e","acronym":"BEGONIA","url":"https://clinicaltrials.gov/study/NCT03742102","created_at":"2021-01-18T18:19:46.394Z","updated_at":"2024-07-02T16:35:02.191Z","phase":"Phase 1/2","brief_title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03742102 - BEGONIA","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 11/14/2024","primary_completion_date":" 11/14/2024","study_txt":" Completion: 11/14/2024","study_completion_date":" 11/14/2024","last_update_posted":"2024-05-21"}]